Treat hyperthyroidism without losing your thyroid.
Hyperthyroidism has two main causes: toxic nodules (treatable with thermal ablation) and Graves’ disease (treatable with medication). Both can be managed while preserving thyroid function. Radioactive iodine and surgery cause permanent hypothyroidism requiring lifelong medication.
The treatment hierarchy depends on the cause. Toxic nodules: thermal ablation normalizes function in 70–90% without hypothyroidism. Graves’ disease: antithyroid medication is first-line, and long-term low-dose therapy keeps many patients in remission. Radioactive iodine and surgery are last resorts that destroy thyroid function permanently.
What is hyperthyroidism?
Hyperthyroidism occurs when the thyroid produces excess thyroid hormone, causing elevated heart rate, anxiety, tremors, weight loss, and heat intolerance. Two distinct causes require different treatment approaches: toxic nodules (nodular disease) and Graves’ disease (autoimmune, whole-gland overactivity).
Toxic nodules (AFTN)
Autonomously functioning thyroid nodules produce excess hormone independent of normal regulation. They can be solitary (a single toxic adenoma) or multiple (toxic multinodular goiter). They gradually develop over years in iodine-deficient areas or as nodules grow.
Key distinction: This is a localized problem. Abnormal nodules produce excess hormone while the rest of the thyroid is normal, which makes them ideal candidates for targeted thermal ablation.
Graves’ disease
An autoimmune condition where antibodies stimulate the entire thyroid gland to overproduce hormone. It is the most common cause of hyperthyroidism in the US. It can cause eye problems (Graves’ ophthalmopathy) in up to half of patients and is more common in women than men.
Key distinction: This is whole-gland disease. The entire thyroid is overactive due to antibody stimulation, so it cannot be treated with focal therapy like ablation. It requires medication, radioactive iodine, or surgery.
Critical point: Treatment depends entirely on the cause. Toxic nodules can be cured with thermal ablation while preserving thyroid function. Graves’ disease requires a different approach: medication first-line, and avoiding radioactive iodine when possible due to poorer long-term outcomes.
Toxic nodules: thermal ablation preserves thyroid function
Thermal ablation destroys toxic nodules using targeted heat, normalizing thyroid function in 70–90% of patients with a solitary toxic adenoma. No hypothyroidism. Outpatient procedure under local anesthesia. It preserves normal thyroid tissue and avoids permanent thyroid destruction.
Clinical outcomes
Solitary toxic adenoma: 70–90% achieve normal thyroid function (TSH normalization) without medication. Toxic multinodular goiter: 25–33% cure rate (lower due to multiple nodules). Volume reduction: 50–85% at 6–12 months.
No hypothyroidism: Ablation destroys only the toxic nodule, preserving normal thyroid tissue. Zero cases of post-ablation hypothyroidism in most studies.
Procedure details
Ultrasound-guided needle insertion under local anesthesia. The moving-shot technique treats the entire nodule systematically. Contrast-enhanced ultrasound confirms complete ablation. Typically 30–60 minutes. Return to activities within 1–3 days.
Complications: Minimal. Transient voice changes are rare and self-limited. No permanent complications in most series. Compare to surgery: permanent voice injury 1–2%, permanent hypoparathyroidism 0–1%.
Best candidates
Solitary toxic adenoma (best results). Nodules under 3 cm have higher success rates. Both subclinical and overt hyperthyroidism are treatable. Patients refusing radioactive iodine or surgery, and those wanting to avoid hypothyroidism.
Second session if needed: If the first ablation is incomplete, a second session achieves normalization in 83% of solitary adenomas, still avoiding hypothyroidism.
Thermal ablation vs radioactive iodine for toxic nodules
Direct comparison shows thermal ablation superior to radioactive iodine for toxic nodules. At 12 months, ablation achieved 91% TSH normalization versus 72% with RAI. The critical difference: ablation caused zero cases of hypothyroidism versus 20% with RAI (5 of 25 patients).
Volume reduction also favored ablation: 76% versus 68% with RAI. Ablation works faster, with most patients normalizing within 3–6 months and discontinuing antithyroid medications. RAI takes longer and carries radiation exposure.
For toxic nodules specifically, thermal ablation should be first-line over radioactive iodine. It preserves thyroid function, avoids radiation, and achieves better outcomes.
Why ablation before RAI or surgery
Preserves thyroid function:Ablation destroys only the toxic nodule, leaving normal thyroid intact. RAI and surgery both cause hypothyroidism requiring lifelong medication.
Better outcomes:91% normalization with ablation versus 72% with RAI, and ablation avoids the 20% hypothyroidism rate seen with RAI treatment of toxic nodules.
Preserves options:If ablation doesn’t achieve cure, RAI or surgery are still available. But RAI and surgery eliminate the ablation option permanently.
Graves’ disease: medication first, avoid radioactive iodine
Graves’ disease is autoimmune: the entire thyroid gland is overactive due to antibody stimulation. It cannot be treated with thermal ablation because it is whole-gland, not focal. Antithyroid medication (methimazole) is first-line and, increasingly, long-term low-dose therapy keeps many patients in remission. Radioactive iodine causes a roughly 95% hypothyroidism rate and worse quality of life than medication or surgery.
Treatment hierarchy for Graves’ disease
The case for long-term medication
For decades the plan was 12–18 months of methimazole, then stop and hope for remission, with relapse in 30–50% of patients. Recent evidence has reshaped that. Longer duration of low-dose therapy substantially improves lasting remission: one landmark program reported relapse of about 15% after roughly 8 years of continuous low-dose treatment, versus about 53% after shorter courses.
A 2025 review in the Journal of Clinical Endocrinology & Metabolism summarized the shift as “small doses, big benefits,” and a 2026 study found continuous low-dose methimazole gave better long-term control of relapsed Graves’ disease than either radioactive iodine or a repeat drug course, without worsening eye disease, weight, or quality of life.
Low-dose methimazole (commonly 2.5–5 mg daily) has a strong safety record: most serious adverse reactions occur in the first 6 months, and after that low-dose maintenance is generally well tolerated. It also preserves every future option, since medication can be stopped and surgery or RAI pursued later. RAI and surgery, once done, cannot be undone.
Why avoid radioactive iodine
About 95% develop hypothyroidism:A nearly universal outcome with current RAI dosing, requiring lifelong thyroid hormone replacement.
Worsens eye disease:RAI roughly doubles the risk of Graves’ ophthalmopathy progression, and is particularly problematic for smokers.
Worse quality of life:A large study (1,186 patients, 6–10 year follow-up) found the RAI group scored worse than medication or surgery on fatigue, anxiety, depression, emotional wellbeing, social and daily life, eye symptoms, and appearance.
Can still fail:Despite the high hypothyroidism rate, RAI still fails to cure hyperthyroidism in about 20% of patients, who then require repeat treatment.
Evidence-based approach for Graves’ disease: Medication first-line, with long-term low-dose methimazole a legitimate durable strategy. If medication truly fails or cannot be tolerated, surgery is generally preferable to radioactive iodine on quality-of-life grounds. RAI should be a last resort.
Hyperthyroidism: symptoms and treatment
“Cured” hyperthyroidism can mean a lifetime of hypothyroid symptoms
Radioactive iodine and surgery are often described as definitive cures. What that phrase leaves out is what comes next: a destroyed thyroid, and lifelong dependence on synthetic hormone. For a meaningful minority of people, that trade is not the clean fix it sounds like.
Dr. Antonio Bianco, a physician-scientist and former president of the American Thyroid Association, has spent his career on exactly this question. His research on how the body converts the storage hormone T4 into the active hormone T3 shows why standard levothyroxine (T4-only) replacement leaves an estimated 10–20% of patients with persistent symptoms, such as fatigue, brain fog, weight gain, and low mood, even when their TSH blood test reads normal.
The lesson is not that thyroid hormone replacement is bad; for most people it works. The lesson is that a normal TSH after your thyroid is destroyed does not guarantee you will feel normal. That uncertainty is a strong argument for preserving your own thyroid whenever the disease allows it, which is precisely what ablation for a toxic nodule, or long-term medication for Graves’ disease, is designed to do.
What the research means for your decision
A working thyroid produces T3 directly and adjusts hour to hour. A pill of T4 cannot replicate that regulation in everyone.
“Normal labs” and “feeling well” are not the same thing for every patient after the gland is gone.
Choosing a thyroid-preserving option keeps this risk off the table entirely. You cannot become dependent on replacement hormone for a gland you still have.
Comparing all treatment options
Treatment choice depends on the cause (toxic nodules vs Graves’ disease). The goal is to control hyperthyroidism while minimizing permanent complications, especially hypothyroidism.
| Outcome | Medication | Thermal Ablation | RAI/Surgery |
|---|---|---|---|
| Works for toxic nodules | Temporary control | Yes (70–90% cure) | Yes (95–100%) |
| Works for Graves’ disease | Yes (first-line) | No (whole gland) | Yes (95–100%) |
| Hypothyroidism risk | 0% | 0% | 95–100% |
| Permanent complications | Rare (liver/allergy) | 0% in most studies | Voice injury, eye disease |
| Quality of life (Graves) | Best long-term | N/A | Worst with RAI |
| Anesthesia required | None | Local only | General (surgery) |
| Recovery time | N/A | 1–3 days | 1–2 weeks (surgery) |
| Preserves thyroid function | Yes | Yes | No (permanent loss) |
Strategic principle: Preserve thyroid function when possible. Toxic nodules: ablation first-line. Graves’ disease: medication first-line, surgery if needed, RAI last resort. Every approach that avoids permanent hypothyroidism also preserves future treatment options.
Doctor Thyroid interviews on preserving thyroid function
RFAMD founder Philip James has interviewed more than 150 thyroid specialists on the Doctor Thyroid podcast. Several go directly to the choices on this page: treating hyperfunctioning nodules with ablation, and why a destroyed thyroid can leave patients unwell on standard replacement.
Dr. Roberto Valcavi: ablation for hyperfunctioning nodules
Dr. Valcavi, with more than 1,800 ablation procedures, discusses treating benign, cystic, and hyperfunctioning (toxic) nodules with radiofrequency ablation while saving the thyroid gland. Directly relevant to toxic-nodule hyperthyroidism.
Dr. Antonio Bianco: why T4-only replacement fails some patients
The former ATA president explains the link between thyroidectomy, lingering hypothyroid symptoms, and T4-only therapy, the core reason to preserve your thyroid rather than destroy it.
Watch and listen
Full interviews with Dr. Valcavi, Dr. Antonio Bianco, and Dr. Emad Kandil on ablation versus surgery are on the Doctor Thyroid channel and podcast.
Frequently asked questions
How do I know if I have toxic nodules or Graves’ disease?
A nuclear medicine scan (radioactive iodine uptake) shows the pattern. Toxic nodules appear as focal “hot spots” with suppressed uptake in the surrounding thyroid. Graves’ disease shows diffusely increased uptake throughout the entire gland. A blood test for TSH receptor antibodies (TRAb) is positive in Graves’ and negative in toxic nodules. Your endocrinologist will order the appropriate testing.
Can thermal ablation treat Graves’ disease?
No. Graves’ disease is whole-gland overactivity caused by antibodies stimulating the entire thyroid. Thermal ablation targets focal lesions (nodules), not diffuse gland stimulation. Ablating portions of the thyroid in Graves’ disease would not cure the underlying antibody problem, and the remaining thyroid would continue overproducing hormone. Graves’ requires medication, RAI, or surgery.
Why do you recommend avoiding radioactive iodine for Graves’ disease?
The evidence shows worse outcomes than the alternatives. RAI causes roughly a 95% hypothyroidism rate, meaning lifelong medication. A large study with 6–10 year follow-up found RAI patients had significantly worse quality of life than the medication or surgery groups, including worse fatigue, anxiety, depression, and impaired daily life. RAI also roughly doubles the risk of worsening Graves’ eye disease. Medication achieves remission in many patients without permanent thyroid destruction, and if it fails, surgery has better quality-of-life outcomes than RAI.
What if my doctor recommends radioactive iodine for my toxic nodule?
Ask about thermal ablation first. Evidence shows ablation achieves 91% normalization versus 72% with RAI for toxic nodules, with zero hypothyroidism versus 20% with RAI. Many endocrinologists are not yet familiar with thermal ablation despite the published data. Request a consultation with a specialist who offers ablation before accepting RAI. If ablation is unavailable in your area, RAI is a reasonable option, but understand the hypothyroidism risk and that ablation would have avoided it.
I have Graves’ disease and don’t want lifelong medication. What should I do?
Start with antithyroid medication (methimazole). Recent evidence shows that longer, low-dose therapy substantially improves lasting remission, so a longer course is often worthwhile before deciding anything is permanent. If you cannot achieve or maintain remission, surgery is generally a better option than RAI based on quality-of-life data. Surgery causes 100% hypothyroidism but avoids the worse outcomes seen with RAI, such as eye disease progression. Both require lifelong thyroid hormone, but surgery has better long-term results.
Can I take antithyroid medication indefinitely?
Yes, and it is an increasingly accepted approach. Many patients choose long-term low-dose methimazole (commonly 2.5–5 mg daily) rather than accepting permanent hypothyroidism from RAI or surgery. It requires regular monitoring (thyroid function every 3–6 months, plus periodic liver function and blood counts). Serious side effects are uncommon and cluster in the first 6 months, and many patients tolerate long-term therapy well. European and Japanese endocrinologists commonly use this approach. Discuss it with your endocrinologist.
Is thermal ablation widely available for toxic nodules?
Availability is increasing but still limited compared to ablation for benign, nonfunctioning nodules. Not all centers offering thyroid nodule ablation treat hyperthyroidism. Seek specialists with specific experience treating toxic nodules with ablation. Some endocrinologists are unfamiliar with the option and may not mention it, so proactive patients should ask specifically about ablation before accepting RAI.
What if thermal ablation doesn’t cure my toxic nodule?
A second ablation session is successful in 83% of solitary toxic adenomas. If a second session is also incomplete, radioactive iodine or surgery remain available. Ablation does not make subsequent RAI or surgery more difficult. This sequential approach maximizes the chance of preserving thyroid function while keeping all options open.
Get appropriate evaluation
Treatment depends on an accurate diagnosis: toxic nodules versus Graves’ disease. Specialists offering both medication management and thermal ablation can provide unbiased guidance matching treatment to your specific condition and preferences.
What to prepare
Laboratory results: TSH, free T4, free T3, and TSH receptor antibodies (TRAb) if tested
Nuclear medicine scan: Radioactive iodine uptake scan showing the uptake pattern if already performed
Thyroid ultrasound: If nodules are identified, bring ultrasound images and any biopsy results
Find a specialist
For toxic nodules, seek centers with specific experience in thermal ablation for hyperthyroidism, not just benign nodules. For Graves’ disease, look for endocrinologists comfortable with long-term medication management who can discuss all three options (medication, surgery, RAI) without bias.
Evidence cited on this page
The guidance above reflects peer-reviewed evidence and current specialist practice. Primary sources:
- Villagelin D, Cooper DS. Low-dose Methimazole in the Long-term Management of Graves’ Disease: Small Doses, Big Benefits. Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf503
- Carlini JA, et al. Treatment outcomes in patients with relapsed Graves’ disease (continuous low-dose methimazole vs radioiodine). Archives of Endocrinology and Metabolism. 2026;70(3).
- Azizi F, et al. Long-term antithyroid drug therapy and relapse rates in Graves’ disease (approximately 15% relapse after long-term therapy vs 53% after shorter courses).
- Bianco AC. Rethinking Hypothyroidism: Why Treatment Must Change and What Patients Can Do, and related work on deiodinases and T4-to-T3 conversion explaining persistent symptoms on levothyroxine-only replacement.
- Comparative studies of radiofrequency ablation versus radioactive iodine for autonomously functioning (toxic) thyroid nodules, reporting higher normalization and lower hypothyroidism with ablation.